Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 15.72 kDa 
• Atom Count: 1,101 
• Modelled Residue Count: 126 
• Deposited Residue Count: 128 
• Unique protein chains: 1

 7MCE

CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH 2-{(7P)-7-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-8-fluoro-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-3-yl}propan-2-ol

• PDB DOI:  https://doi.org/10.2210/pdb7MCE/pdb

• Classification: CELL CYCLE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)
• Mutation(s): No 


• Deposited: 2021-04-02 Released: 2021-09-29 
• Deposition Author(s): Sheriff, S.
• Funding Organization(s): Other private

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.76 Å
• R-Value Free: 0.288 
• R-Value Work: 0.243 
• R-Value Observed: 0.246 

Literature

Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype.

Hill, M.D., Quesnelle, C., Tokarski, J., Fang, H., Fanslau, C., Haarhoff, Z., Kramer, M., Madari, S., Wiebesiek, A., Morrison, J., Simmermacher-Mayer, J., Sinz, M., Westhouse, R., Xie, C., Zhao, J., Huang, L., Sheriff, S., Yan, C., Marsilio, F., Everlof, G., Zvyaga, T., Lee, F., Gavai, A.V., Degnan, A.P.

(2021) Bioorg Med Chem Lett 51: 128376-128376

• PubMed: 34560263 
• DOI: https://doi.org/10.1016/j.bmcl.2021.128376
• Primary Citation of Related Structures:  
  7MCE


• PubMed Abstract: 
  

We describe our efforts to introduce structural diversity to a previously described triazole-containing N1-carboline series of bromodomain and extra-terminal (BET) inhibitors. N9 carbolines were designed to retain favorable binding interactions that the N1-carbolines possess. A convergent synthetic route enabled modifications to reduce clearance, enhance physicochemical properties, and improve the overall in vitro profile. This work led to the identification of a potent BET inhibitor, (S)-2-{8-fluoro-5-[(3-fluoropyridin-2-yl)(oxan-4-yl)methyl]-7-[4-( ² H ₃ )methyl-1-methyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-3-yl}propan-2-ol (10), a compound with enhanced oral exposure in mice. Subsequent evaluation in a mouse triple-negative breast cancer tumor model revealed efficacy at 4 mg/kg of N9-carboline 10.

---

Organizational Affiliation: 

Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Bromodomain-containing protein 4	A	128	Homo sapiens	Mutation(s): 0  Gene Names: BRD4, HUNK1
UniProt & NIH Common Fund Data Resources
Find proteins for O60885 (Homo sapiens) Explore O60885  Go to UniProtKB:  O60885
PHAROS:  O60885

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
YWY (Subject of Investigation/LOI)	B [auth A]	2-{(7P)-7-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-8-fluoro-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-3-yl}propan-2-ol C30 H32 F N5 O2 AIWLOFZSVQLGOB-GDLZYMKVSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.76 Å
• R-Value Free: 0.288 
• R-Value Work: 0.243 
• R-Value Observed: 0.246 
• Space Group: P 3₁ 2 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 42.5	α = 90
b = 42.5	β = 90
c = 124.9	γ = 120

Software Package:

Software Name	Purpose
HKL-2000	data reduction
HKL-2000	data scaling
PHASER	phasing
BUSTER	refinement
PDB_EXTRACT	data extraction

Structure Validation

Entry History & Funding Information

Deposition Data

• Released Date: 2021-09-29 
Deposition Author(s): Sheriff, S.

---

Funding Organization	Location	Grant Number
Other private	United States	--

Revision History  

• Version 1.0: 2021-09-29
  Type: Initial release
  
• Version 1.1: 2021-10-06
  Changes: Database references